A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
AstraZeneca
Study ID
NCT06792695
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 130 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Key Dates

Start date
Mar 12, 2025
Status verified
May 2026
Primary completion
May 31, 2027
Completion
Jun 7, 2028

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Volrustomig + FOLFIRI+ Bevacizumab group (Arm A)
    Participants will receive FOLFIRI and bevacizumab together with volrustomig.
  • Active Comparator: FOLFIRI+ BEVACIZUMAB group (Arm B)
    Partcipants will receive FOLFIRI and bevacizumab.

Primary Outcome Measure

Progression Free Survival (PFS) [ Time Frame: Approximately 3 years ]

Central Contacts

Locations (14)

FacilityCityStateZIPSite coordinators
Research SiteScottsdaleArizona85259-
Research SiteLos AngelesCalifornia90089-
Research SiteWashington D.C.District of Columbia20007-
Research SiteChicagoIllinois60637-
Research SiteBaltimoreMaryland21224-
Research SiteBostonMassachusetts02114-
Research SiteRochesterMinnesota55905-
Research SiteTrentonNew Jersey08690-
Research SiteRochesterNew York14618-
Research SiteClevelandOhio44106-
Research SitePortlandOregon97239-
Research SitePhiladelphiaPennsylvania19104-
Research SiteNashvilleTennessee37232-
Research SiteHoustonTexas77030-

Find similar trials in Scottsdale, AZ

By research site
Research Site· Scottsdale, AZResearch Site· Los Angeles, CAResearch Site· Washington D.C., DCResearch Site· Chicago, ILResearch Site· Baltimore, MDResearch Site· Boston, MA

Related Studies